How the FDA Drug Approval Process Works

TLDR

The FDA evaluates new U.S. prescription drugs through five broad stages: discovery and development, preclinical research, clinical research, regulatory review, and post-market monitoring. Before clinical trials can begin, a sponsor generally submits an Investigational New Drug application. After gathering evidence, the sponsor may submit a New Drug Application for a conventional drug or a Biologics License Application for a biological product. FDA reviewers assess benefits, risks, manufacturing quality, and proposed labeling for a particular use. Approval does not mean zero risk, and safety monitoring continues after the medicine reaches the market.

This guide offers the FDA drug approval process explained in practical terms. Its focus is the high-level U.S. pathway for new human prescription drugs and biological products—not the distinct pathways used for generic drugs, biosimilars, compounded products, medical devices, or every nonprescription medicine.

The most important point is that FDA approval is a benefit–risk decision for a specific labeled use. It means the agency found adequate evidence to support approval under defined conditions, not that the medicine is harmless, appropriate for every person, or proven for every possible use. The FDA’s overview of drug development and approval provides the official framework.

The FDA drug approval process explained in five stages

FDA presents development as a connected pathway rather than a single approval test. The familiar five-stage map makes the process easier to understand, although actual development programs can overlap, change direction, or use designs tailored to the medicine and disease.

Stage	Main question	Typical work
Discovery and development	Could this candidate become a useful medicine?	Candidate identification, laboratory characterization, formulation work, and early study of how the substance behaves
Preclinical research	Is there enough information to justify testing in people?	Laboratory and animal studies examining pharmacology and potential toxicity
Clinical research	What happens when people receive the investigational drug?	Studies evaluating dosage, safety, biological effects, and evidence of benefit
FDA review	Does the evidence support approval for the proposed use?	Review of clinical and nonclinical evidence, manufacturing quality, inspections, and labeling
Post-market monitoring	What can be learned from wider and longer use?	Safety reports, active surveillance, required studies, label updates, and risk-management measures

Many candidates never complete this pathway. Early work may reveal unacceptable toxicity, limited biological activity, manufacturing difficulty, or insufficient evidence of benefit. Development decisions therefore depend on the full evidence package rather than on success at one isolated step.

Before an investigational drug is given to people

Preclinical research happens before routine human testing. Researchers use laboratory and animal studies to investigate pharmacology and potential toxicity. They may also study absorption, metabolism, excretion, dosing, and possible interactions. The aim is not to prove that the candidate will work in patients. It is to build enough information to decide whether carefully controlled human research is reasonable.

The IND opens a research pathway—not a commercial market

To begin clinical investigation in the United States, a sponsor generally uses an Investigational New Drug application, commonly called an IND. The submission gives FDA information about the candidate, preclinical findings, manufacturing, proposed study protocols, and investigator qualifications. The purpose is to support clinical investigation while addressing unreasonable risks to participants.

An IND is not marketing approval. A product described as “investigational” or “being studied under an IND” has not thereby been approved for sale as a prescription medicine. Institutional review boards also have a role in reviewing clinical research before participants are enrolled.

What Phase 1, Phase 2, and Phase 3 trials do

Clinical development is often described in three phases. These labels identify the usual purpose and maturity of the research, but they should not be treated as a rigid checklist. Programs can use adaptive studies, combine elements of different phases, or pursue evidence strategies suited to a rare disease, a large public-health problem, or an existing treatment landscape.

Phase 1: initial human safety and dosage

Phase 1 usually examines initial safety, dosage, tolerability, and how the body handles the drug. Depending on the treatment, participants may be healthy volunteers or people with the condition under study. These trials can identify common short-term reactions and inform the doses evaluated next, but their limited size and duration cannot reveal every risk.

Phase 2: early evidence of benefit

Phase 2 generally studies people who have the target condition. Investigators continue evaluating safety while looking for early evidence that the drug produces the intended clinical or biological effect. Results can influence the selected dose, endpoint, participant population, and design of later studies.

A promising Phase 2 result is not the same as approval. Results can be affected by the comparator, endpoint, follow-up period, participant characteristics, and study design. Understanding what a placebo-controlled trial is designed to show can help readers interpret these findings more carefully.

Phase 3: a broader benefit–risk picture

Phase 3 generally gathers more extensive evidence about benefits and adverse effects in larger populations. These studies often provide important support for the proposed indication, dosing, warnings, and instructions in the eventual prescribing information.

There is no useful blanket rule that every medicine must complete exactly two conventional Phase 3 trials. The evidence needed depends on applicable legal standards, the strength and consistency of the results, the condition, trial design, endpoints, and the total evidence package. The practical question is whether the submitted evidence adequately supports the proposed use—not whether every program follows an identical sequence.

The marketing application: NDA or BLA

When a sponsor believes the evidence supports marketing, it submits an application for FDA review. Most conventional new drugs use a New Drug Application, or NDA. Biological products generally use a Biologics License Application, or BLA. These applications follow related benefit–risk principles, but the legal and technical pathways differ.

A marketing application is much more than a collection of favorable trial summaries. It can contain complete clinical and nonclinical analyses, information about adverse events, proposed dosing, manufacturing and quality data, statistical analyses, and proposed prescribing information. FDA reviewers use this package to evaluate whether the product can be made consistently and whether the evidence supports the claims that would appear in its label.

What FDA evaluates before making a decision

FDA review is multidisciplinary. Depending on the application, physicians, statisticians, pharmacologists, toxicologists, chemists, microbiologists, manufacturing specialists, and other experts may examine different parts of the submission. Review can also include manufacturing-facility inspections and detailed negotiation of the prescribing information.

The central question is whether the drug’s demonstrated benefits outweigh its known and potential risks for the proposed conditions of use. That assessment depends on the seriousness of the condition, available treatments, magnitude and certainty of benefit, nature of the risks, and how those risks can be communicated or managed.

For some applications, FDA convenes an advisory committee of outside experts for public discussion and recommendations. The committee’s vote is advice; FDA makes the regulatory decision.

Approval versus a complete response letter

If the application meets the applicable requirements, FDA may approve it with agreed prescribing information. If issues prevent approval at that time, the agency may issue a complete response letter describing deficiencies that must be addressed. Such a letter is not approval, but it does not necessarily mark the permanent end of development; a sponsor may be able to conduct more work and resubmit.

What “FDA approved” actually means

Approval attaches to specific conditions described in the label. These can include the indication, intended population, dosage and administration, contraindications, warnings, precautions, drug interactions, and known adverse reactions. A medicine approved for one disease or population is not automatically approved for another.

It is better to ask whether a medicine is approved for a particular use than simply whether it is “FDA approved.” The distinction matters because benefit and risk can change with dose, patient characteristics, other treatments, and the outcome being targeted. Approval also does not mean every possible adverse effect is known. Some uncommon, delayed, or population-specific problems become detectable only after much wider use.

Readers interpreting study outcomes should also examine the size of the benefit, not only whether a result was statistically significant. The difference between relative risk and absolute risk can substantially change how meaningful a treatment effect looks.

Expedited programs do not all mean the same thing

Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review are four distinct FDA programs for serious conditions. A designation or review pathway is not itself approval, and the terms should not be used interchangeably.

Fast Track is intended to facilitate development and expedite review of drugs addressing serious conditions and unmet medical needs.
Breakthrough Therapy designation can provide more intensive FDA guidance when preliminary clinical evidence indicates the drug may offer substantial improvement over available therapy on clinically significant endpoints.
Accelerated Approval can allow approval based on a qualifying surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, generally with confirmatory evidence required after approval.
Priority Review changes FDA’s review goal for an application. It does not lower the evidentiary standard or mean the application will be approved.

These programs can affect communication, development, the evidence supporting an initial decision, or the review timetable. They do not all make clinical trials shorter, and none should be read as proof that a treatment is superior before FDA has evaluated the relevant evidence. The FDA’s expedited-program comparison explains the distinctions.

What happens after approval

FDA oversight continues because preapproval trials cannot provide complete safety information. Once a medicine is used by a larger and more varied population—sometimes for longer periods or alongside other treatments—new safety patterns may emerge.

Post-market oversight can include spontaneous adverse-event reports through FAERS and MedWatch, active surveillance through the Sentinel System, post-market studies, required clinical trials, inspections, safety communications, labeling changes, and Risk Evaluation and Mitigation Strategies. In some circumstances, regulatory action can include restricting use or withdrawing approval.

An adverse-event report is a signal, not proof of causation. Reports may be incomplete, duplicated, influenced by other illnesses or medicines, or submitted without confirmation that the drug caused the event. FDA analyzes patterns and combines reports with other evidence to determine whether further investigation or action is warranted.

This distinction also applies when reading trial reports: an adverse event is something that happened after treatment, while a side effect implies a stronger causal connection. Our guide to adverse events versus side effects explains how to read those safety terms.

How to check the status of a specific medicine

Start with Drugs@FDA, which provides public information on many approved drug products, including prescribing information, approval letters, and review materials. Search by active ingredient as well as brand name because several products can contain the same ingredient.

Confirm that the exact product appears in an official FDA database.
Open the current prescribing information rather than relying on promotional summaries or old news reports.
Check the indication and intended population, not just the product name.
Review major warnings, contraindications, dosage instructions, and the approval date.
Look for later FDA safety communications or label updates when current risk information matters.

A mention in a clinical-trial registry, an IND, a press release, or an expedited-program announcement does not establish marketing approval. The decisive evidence is an FDA approval record for the product and use in question.

Frequently asked questions

Is an IND the same as FDA approval?

No. An IND supports the clinical investigation of an unapproved drug in the United States. It does not authorize routine commercial marketing and should not be presented as evidence that the treatment has been approved.

What is the difference between an NDA and a BLA?

An NDA is the usual marketing application for a conventional new drug. A BLA is generally used for biological products. Both require substantial evidence and manufacturing information, but they operate under distinct regulatory frameworks.

Does every drug need two Phase 3 trials?

Not as a universal rule. The required evidence depends on the product, condition, study quality, consistency of findings, endpoints, and applicable regulatory standards. Phase 3 is a useful description of later-stage research, not a guarantee that every development program has the same number or design of trials.

Does Accelerated Approval mean the evidence is weaker?

Accelerated Approval may rely on a qualifying surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. Continued approval can depend on confirmatory evidence verifying the anticipated benefit. It is a specific approval pathway, not merely a faster review label.

Are medicines still monitored after approval?

Yes. FDA uses adverse-event reporting, active surveillance, post-market studies, labeling changes, risk-management programs, and other regulatory tools. Monitoring matters because some risks cannot be fully characterized before a medicine enters wider use.

The practical takeaway

The FDA drug approval process is best understood as an evidence pathway rather than a single pass-or-fail experiment. Preclinical findings support the move into human research; clinical trials build the benefit–risk case; an NDA or BLA brings the complete package to FDA; and post-market systems continue evaluating safety after approval.

When assessing a medicine, ask four questions: What exact use was approved? Which population was studied? How large and certain was the benefit? What risks, warnings, or post-market requirements remain? Those questions provide a more accurate understanding than treating “FDA approved” as a blanket promise of safety or effectiveness.